{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-151009","form_type":"8-K","ticker":null,"cik":"0001840574","company_name":"Verve Therapeutics, Inc.","filed_at":"2024-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.664978+00:00","generated_at":"2026-06-01T07:14:23.035757+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Verve Therapeutics appoints Troy Lister as CSO; Andrew Bellinger to resign effective June 21, 2024","bullets":["Troy Lister, Ph.D., appointed Chief Scientific Officer effective June 21, 2024, succeeding Andrew Bellinger.","Andrew Bellinger resigns as CSO on June 21, 2024; will provide advisory services under an Advisor Agreement.","Bellinger receives 12 months base salary continuation, a $153,765 bonus (67% of target), and limited equity vesting.","Advisor Agreement pays Bellinger $200/hour; cannot be terminated for convenience before two-year anniversary.","Bellinger subject to non-compete for one year after advisor termination; non-disclosure obligations continue."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-151009","json":"https://secwatch.observer/filing/0001193125-24-151009.json","markdown":"https://secwatch.observer/filing/0001193125-24-151009.md","text":"https://secwatch.observer/filing/0001193125-24-151009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840574/000119312524151009/0001193125-24-151009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840574/000119312524151009/d797150d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:14:23.035757+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3aa886b0f9","claim":"Andrew Bellinger resigned as Chief Scientific Officer at Verve Therapeutics, Inc..","evidence_excerpt":"Andrew Bellinger, M.D., Ph.D., who will resign as the Company's Chief Scientific Officer on the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840574/000119312524151009/0001193125-24-151009-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"f93654de30","claim":"Troy Lister was appointed as Chief Scientific Officer at Verve Therapeutics, Inc..","evidence_excerpt":"appointed Troy Lister, Ph.D., as Chief Scientific Officer of the Company, effective June 21, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840574/000119312524151009/0001193125-24-151009-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}